Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes.

Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes. Abstract Text:

J Weyer,I V Kuzmin,C E Rupprecht,L H Nel,

SUMMARYLyssaviruses cause acute, progressive encephalitis in mammals. Current rabies vaccines offer protection against the lyssaviruses, with the notable exceptions of Mokola virus (MOKV), Lagos bat virus (LBV) and West Caucasian bat virus (WCBV). Here we describe the cross-protective and cross-reactive immune responses induced by experimental recombinant vaccinia viruses encoding the glycoprotein genes of rabies virus (RABV), MOKV and WCBV, either singly or in dual combinations. Constructs expressing a single glycoprotein gene protected mice against lethal intracranial challenge with homologous virus. Similarly, recombinants expressing glycoprotein genes from two different lyssaviruses offered mice protection against both homologous viruses. VNAb induced by vaccines that included a MOKV glycoprotein gene cross-neutralized LBV, but not WCBV. We concluded that a single recombinant poxvirus-vectored vaccine including MOKV and RABV glycoprotein genes, should be a major addition to available rabies biologics and should offer broad protection against all of the lyssaviruses, except WCBV.

Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes. Publishing Authors By Initials

J Weyer,IV Kuzmin,CE Rupprecht,LH Nel,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Epidemiology and infection

VOLUME: 136

Page Numbers: 670-8

Journal Abbreviation: Epidemiol. Infect.

ISSN: 0950-2688

DAY: 22

MONTH: 06

YEAR: 2007

Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8703737

Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes.

AFFILIATION: University of Pretoria, Department of Microbiology and Plant Pathology, Pretoria, South Africa.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Epidemiol Infect

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes Related Publications

• Ambient particulate pollutants in the ultrafine range promote early atherosclerosis and systemic oxidative stress.
• Basal-cell carcinoma of the vulva; review of the literature and report of a case.
• Clinical evaluation of higher stimulation rates in the nucleus research platform 8 system.
• Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes.
• Development and validation of a short questionnaire to assess sodium intake.
• Dr. Ivan Toms--a true hero.
• Epidemiology and pathogenicity of African bat lyssaviruses.
• Fads and fallacies of diet.
• Fossil evidence for the early ant evolution.
• Glutathione depletion inhibits dendritic cell maturation and delayed-type hypersensitivity: implications for systemic disease and immunosenescence.
• Impairment of mitochondrial function by particulate matter (PM) and their toxic components: implications for PM-induced cardiovascular and lung disease.
• Importance of oxidative stress in the pathogenesis and treatment of asthma.
• Intravenous fluid therapy: a randomized controlled trial to investigate the effectiveness of the IV(2) flow medical device.
• Low dose radiotherapy for adenotonsillar lymphoid hyperplasia in HIV-positive patients.
• Mokola virus in domestic mammals, South Africa.
• Molecular epidemiology of rabies in bat-eared foxes (Otocyon megalotis) in South Africa.
• Nanobiology: Particles slip cell security.
• Nrf2 activation by sulforaphane restores the age-related decrease of T(H)1 immunity: Role of dendritic cells.
• Occurrence of environmental atypical mycobacteria in South Africa.
• Phylogeny of Lagos bat virus: Challenges for lyssavirus taxonomy.
• Preoperative nutritional status and prognostic nutritional index in patients with benign disease undergoing abdominal operations--Part I.
• Preoperative nutritional status and prognostic nutritional index in patients with benign disease undergoing abdominal operations--Part II.
• Pro-oxidative DEP chemicals induce heat shock proteins and an unfolding protein response in a bronchial epithelial cell line as determined by DIGE analysis.
• Q&A: Creations from the cosmos. Interviewed by Jennifer Rohn.
• Retirement: Miss Henrietta Nel.
• T-cell effector pathways in allergic diseases: Transcriptional mechanisms and therapeutic targets.
• The manifestation of middle ear pathology in an elderly group.
• The role of reactive oxygen species and oxidative stress in mediating particulate matter injury.
• Use of a molecular epidemiological database to track human rabies case histories in South Africa.